Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04887298 · ClinicalTrials.gov registry record · Phase 1
Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases
A Phase 1 study, sponsored by Moleculin Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT04887298 is a Phase 1 study that has completed, run by Moleculin Biotech. The registered enrollment target is 36 participants.
The verdict
NCT04887298, a Phase 1 study, has completed, sponsored by Moleculin Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and in Phase 2 will explore the efficacy of L- Annamycin as a single agent for the treatment of subjects with STS with lung metastases for which chemotherapy is considered appropriate.
Interventions
- DRUG Liposomal Annamycin (L-Annamycin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-06-05 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04887298
The ClinicalTrials.gov registry entry for NCT04887298 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Moleculin Biotech, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Liposomal Annamycin (L-Annamycin) is the first listed.
NCT04887298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04887298 about?
NCT04887298 is a clinical study titled "Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases". This is a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and in Phase 2 will explore the efficacy of L- Annamycin as a single agent for the treatment of subjects with STS with lung...
What is the current status of trial NCT04887298?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-06-05. Estimated completion is 2024-08-06.
What interventions are being tested in trial NCT04887298?
The interventions under investigation include: Liposomal Annamycin (L-Annamycin) (DRUG).
Who is sponsoring clinical trial NCT04887298?
This trial is sponsored by Moleculin Biotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.